本文選題：骨 + 組織工程��； 參考：《第一軍醫(yī)大學(xué)》2006年博士論文

【摘要】：由創(chuàng)傷、感染、腫瘤等疾病引起的骨缺損是骨科臨床的常見(jiàn)病，骨缺損治療的難題主要是移植骨的來(lái)源問(wèn)題。組織工程的興起和發(fā)展為骨缺損的修復(fù)開(kāi)辟了一條新的途徑。骨組織工程技術(shù)以體外構(gòu)建、體內(nèi)重組的模式給這一領(lǐng)域提供了嶄新的治療技術(shù)手段，成為目前修復(fù)骨缺損的較為理想的方法。 隨著研究的深入，骨組織工程已逐步由動(dòng)物實(shí)驗(yàn)擴(kuò)展到臨床實(shí)驗(yàn)階段。臨床應(yīng)用不同于動(dòng)物實(shí)驗(yàn)，首先需要考慮治療的安全性，因此組織工程種子細(xì)胞的選擇，材料的選擇以及種子細(xì)胞的體外培養(yǎng)過(guò)程等問(wèn)題都是需要謹(jǐn)慎注意的。富血小板血漿是經(jīng)過(guò)特殊方法提取的血小板含量豐富的血漿，相較普通血清含有更豐富的細(xì)胞因子。研究表明細(xì)胞因子是骨髓基質(zhì)干細(xì)胞增值、分化的必須。本研究以自體骨髓基質(zhì)干細(xì)胞作為種子細(xì)胞，嘗試采用自體富血小板血漿替代普通血清——盡量排除異類(lèi)抗原物質(zhì)的引入且利于促進(jìn)細(xì)胞的增值、分化的培養(yǎng)方法，誘導(dǎo)培養(yǎng)人骨髓基質(zhì)干細(xì)胞，并將誘導(dǎo)培養(yǎng)的骨髓基質(zhì)干細(xì)胞與臨床應(yīng)用相對(duì)成熟具有臨床應(yīng)用許可的北京意華健公司的YHJ500珊瑚羥基磷灰石材料復(fù)合植入裸鼠體內(nèi)。探討了自體富血小板血漿對(duì)誘導(dǎo)培養(yǎng)人骨髓基質(zhì)干細(xì)胞生物學(xué)特性的影響及以自體富血小板血漿誘導(dǎo)培養(yǎng)的人骨髓基質(zhì)干細(xì)胞與珊瑚羥基磷灰石材料的生物相容性及在體內(nèi)的成骨效用。 由于自體骨髓基質(zhì)干細(xì)胞培養(yǎng)、擴(kuò)增需很長(zhǎng)時(shí)間且針對(duì)年齡較大或存在其他疾患的個(gè)體又無(wú)法完成自體的骨髓基質(zhì)干細(xì)胞的培養(yǎng)與擴(kuò)增，因此建立人骨髓基質(zhì)干細(xì)胞庫(kù)是組織工程在臨床推廣應(yīng)用的必須。研究證實(shí)異體骨髓基質(zhì)干細(xì)
[Abstract]:By trauma, infection, tumor and other diseases caused by bone defect is a common disease in clinical department of orthopedics, problems in the treatment of bone defect is the main source of bone graft. The rise and development of tissue engineering provides a new way for the repair of bone defect. Bone tissue engineering technique to construct the recombinant in vitro, in vivo model provide a new treatment technology for this field, becoming the bone defect repair is an ideal method.
With the in-depth study, bone tissue engineering has been gradually extended from animal experiments to clinical trials. The clinical application is different from the animal experiments, first of all need to consider the safety of the treatment, the seed cells of tissue engineering, material selection and seed cells in vitro culture process is need careful attention. Platelet rich the plasma is extracted by special method in platelet rich plasma, compared with common serum contained more rich cytokine. The study showed that the cell factor is bone marrow stromal stem cell differentiation. This value must be studied with autologous bone marrow stromal stem cells as seed cells, try using autologous platelet rich plasma instead of normal serum -- try to exclude alien the introduction of an antigenic substance promote cell proliferation and differentiation, cultivation method, induced culture of human bone marrow stromal stem cells, and induced YHJ500 coral hydroxyapatite composite implantation of bone marrow stromal stem cell culture and clinical application of the relatively mature clinical application has permitted Beijing Huajian company. Discusses the compatibility and in vivo osteogenic effect of autologous platelet rich plasma effects on the biological characteristics of cultured human bone marrow stromal stem cells and autologous platelet rich plasma cultured human bone marrow stromal stem cells and coralline hydroxyapatite biological materials.
Because of autologous bone marrow stromal stem cell culture, expansion and take a long time for older or have other disorders of the individual is unable to complete the cell culture and amplification of bone marrow stromal stem autologous, so the establishment of human bone marrow stromal stem cell bank is tissue engineering in clinical application. It must be confirmed that allogeneic bone marrow stromal stem cells

【學(xué)位授予單位】：第一軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2006
【分類(lèi)號(hào)】：R329.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 余升華,蔡道章,林淦松,胡漢生,鄭秀玲,彭文明,劉水寶;骨形態(tài)發(fā)生蛋白和纖維蛋白復(fù)合物修復(fù)關(guān)節(jié)軟骨全層缺損[J];廣東醫(yī)學(xué);1999年10期

2 孫沫逸,丁鴻才,毛天球;骨基質(zhì)明膠的研究概況[J];國(guó)外醫(yī)學(xué).口腔醫(yī)學(xué)分冊(cè);1990年03期

3 林敏魁,閆福華;富血小板血漿用于牙周組織再生的研究 Ⅰ、PRP的提取及對(duì)PDLFs增殖的影響[J];臨床口腔醫(yī)學(xué)雜志;2003年11期

4 羅靜聰,楊志明;纖維蛋白膠的制備及其在組織工程中的應(yīng)用[J];生物醫(yī)學(xué)工程研究;2004年03期

5 劉彥春,王煒,曹誼林,商慶新,鐘偉;卵磷脂、多聚賴(lài)氨酸和PLA包埋PGA與軟骨細(xì)胞體外培養(yǎng)的實(shí)驗(yàn)研究[J];實(shí)用美容整形外科雜志;1997年05期

6 梁衛(wèi)東,石應(yīng)康;細(xì)胞培養(yǎng)法評(píng)價(jià)生物材料生物相容性研究進(jìn)展[J];生物醫(yī)學(xué)工程學(xué)雜志;1999年01期

7 楊曉芳,奚廷斐;生物材料生物相容性評(píng)價(jià)研究進(jìn)展[J];生物醫(yī)學(xué)工程學(xué)雜志;2001年01期

8 李娟,張耀庭,曾偉,羅璇,廖長(zhǎng)春;應(yīng)用考馬斯亮藍(lán)法測(cè)定總蛋白含量[J];中國(guó)生物制品學(xué)雜志;2000年02期

9 閆玉化，，許原，戴紅蓮，賀建華;可降解β－Ca_3（PO_4）_2陶瓷的物化性能與生物性能[J];武漢工業(yè)大學(xué)學(xué)報(bào);1995年04期

10 鄭啟新，杜靖遠(yuǎn)，夏志道，王洪;磷酸三鈣陶瓷人工骨的細(xì)胞相容性研究[J];武漢工業(yè)大學(xué)學(xué)報(bào);1995年04期

本文編號(hào)：1771906